palmitoylethanolamide.com.au
HomeResearchJulia 2018

Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy

Julia M Post, Sebastian Loch, Raissa Lerner, Floortje Remmers, Ermelinda Lomazzo, Beat Lutz, Laura Bindila. Front Mol Neurosci. 2018 Mar 14;11:67.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Mice with kainic acid-induced acute seizures
Dose used in the study
PEA given by intraperitoneal injection, acute and subchronic; exact mg/kg not stated in the abstract
Duration
Endocannabinoid and eicosanoid levels tracked over 180 minutes post-seizure; subchronic dosing also tested
What was measured
Seizure intensity, neuroprotection, and hippocampal/plasma endocannabinoid and eicosanoid levels, compared with FAAH blockade

What the authors reported

Subchronic PEA significantly lessened seizure intensity, promoted neuroprotection, and changed plasma and hippocampal endocannabinoid and eicosanoid levels after kainic acid-induced seizures in mice.

Limits of this study

A mouse model of acute seizures; it cannot show effect in people with epilepsy. Funding and conflicts not stated in the abstract.

Source

PubMed 29593494 · doi:10.3389/fnmol.2018.00067

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.